Glenmark Pharmaceuticals (GLENMARK.NS) Stock Price
Glenmark Pharmaceuticals Price
Over the last 19 years Glenmark Pharmaceuticals grew revenue by 14.6% annually, reaching 167.11 B INR. Earnings per share have grown at 7.8% per year over the last 19 years. For Glenmark Pharmaceuticals, the net margin of 8.1% is broadly stable versus 7.7% a few years ago. At today's price the dividend yield works out to roughly 0.19%. The payout ratio is around 15% of earnings. The dividend has grown at 8.3% per year over the past 19 years. The consensus 12-month price target for Glenmark Pharmaceuticals is 2,305.20 INR, about 13.9% below where the stock trades today. Of 17 analysts, 14 rate the stock a buy — an overall Buy consensus.
Glenmark Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Glenmark Pharmaceuticals business model & stock analysis
Frequently asked questions about Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. operates on a highly efficient business model focused on the development, manufacturing, and distribution of innovative pharmaceutical products. The company follows a research-oriented approach and endeavors to bring affordable, high-quality drugs to patients across the globe. Glenmark Pharmaceuticals specializes in the areas of dermatology, respiratory, oncology, and several other therapeutic segments. By leveraging its strong R&D capabilities and global manufacturing infrastructure, the company aims to address unmet medical needs and improve healthcare accessibility. Glenmark Pharmaceuticals' business model emphasizes continuous innovation, strategic partnerships, and expansion into new markets, reinforcing its position as a leading pharmaceutical player in the industry.
Glenmark Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.
The main competitors of Glenmark Pharmaceuticals Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy's Laboratories Ltd, and Lupin Ltd. These companies are also leading players in the pharmaceutical industry and compete with Glenmark Pharmaceuticals in terms of product offerings, market share, and innovation.
Glenmark Pharmaceuticals Ltd. is a renowned pharmaceutical company with a rich history and background. Founded in 1977 by Gracias Saldanha, it started as a generic drug manufacturer in Mumbai, India. Over the years, Glenmark has grown into a global player in the pharmaceutical industry, focusing on research and development of innovative therapeutics. The company has a diverse portfolio, covering various therapeutic areas such as dermatology, respiratory, and oncology. Glenmark has consistently shown its commitment to quality and affordability, making healthcare accessible to a larger population. With its global presence and cutting-edge research, Glenmark Pharmaceuticals Ltd. continues to make significant contributions to the healthcare industry.
Some significant milestones achieved by Glenmark Pharmaceuticals Ltd include: 1. The development and commercialization of several innovative and patent-protected drugs in various therapeutic categories. 2. Successful market expansion globally, with presence in over 80 countries and a strong focus on emerging markets. 3. Consistent growth in revenue and profitability over the years, establishing a strong financial position in the pharmaceutical industry. 4. Launching of the first biosimilar monoclonal antibody, marking a breakthrough in the field of biotherapeutics. 5. Collaborations and partnerships with renowned pharmaceutical companies, enabling the company to leverage expertise and expand its product portfolio. 6. Achieving regulatory approvals for various drugs, demonstrating compliance with international quality standards. 7. Initiatives for research and development, encouraging innovation and driving the company's future growth.
Glenmark Pharmaceuticals Ltd primarily operates in various countries and regions worldwide. The company has a significant presence in India, where it is headquartered and has a strong market presence. Additionally, Glenmark Pharmaceuticals has established operations and a market presence in several other countries, including the United States, Europe, Latin America, and Asia-Pacific regions. With its global footprint, Glenmark Pharmaceuticals continues to expand its reach and deliver innovative healthcare solutions to patients around the world.
Glenmark Pharmaceuticals Ltd represents a strong commitment to innovation, quality, and patient-centricity. The company focuses on delivering affordable and accessible healthcare solutions for people worldwide. With a vision to be a leading global pharmaceutical company, Glenmark Pharmaceuticals embraces a corporate philosophy centered around integrity, transparency, and ethical practices. By continually investing in research and development, Glenmark Pharmaceuticals strives to develop new and improved treatments to address unmet medical needs. Through its relentless efforts, the company aims to make a positive impact on the lives of patients and contribute to the growth and well-being of the healthcare industry.
Analysts currently set an average price target of 2,216.96 INR for the Glenmark Pharmaceuticals stock (median: 2,305.20 INR), implying -15.2 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Glenmark Pharmaceuticals stock: 14 recommend buying, 2 holding and 1 selling.
Converted at the current exchange rate, the Glenmark Pharmaceuticals share trades at 26.12 EUR (2,677.00 INR).
The Glenmark Pharmaceuticals share (GLENMARK.NS) is listed on 2 stock exchanges, including: NSE (Indien) (GLENMARK.NS).
Glenmark Pharmaceuticals Ltd is a multinational pharmaceutical company based in Mumbai, India. The company operates in several sectors, including the development, manufacturing, and marketing of prescription drugs, generic medicines, active pharmaceutical ingredients, and over-the-counter products. In the area of prescription medicines, Glenmark has obtained approvals for a wide range of products that can be used to treat various diseases and disorders. These include therapies for respiratory diseases, dermatology, ophthalmology, oncology, pain management, women's healthcare, and many more. An important aspect of their business strategy is to continuously invest in research and development to expand and improve their product range. Glenmark has also specialized in the manufacturing of generic medicines and offers an extensive range of generic drugs. These include well-known brand-name medicines such as Atorvastatin, Pioglitazone, Sertraline, Olanzapine, and a variety of other medications. Glenmark has a strong presence in numerous countries around the world and has established itself as a reliable, high-quality supplier of generic medicines. Another important area of Glenmark Pharmaceuticals is the manufacturing of active pharmaceutical ingredients (APIs). Here, the company produces high-quality ingredients that are used in a variety of medications, from antibiotics and analgesics to antidepressants and cardiovascular drugs. Glenmark has multiple manufacturing facilities that operate according to the strictest international standards. In addition to prescription drugs, generic medicines, and APIs, Glenmark also produces a range of over-the-counter products. These can be purchased without a prescription and include a wide variety of products, such as painkillers, cough and cold remedies, multivitamin supplements, antacids, and anti-fungal products. Glenmark has carefully selected portfolio of OTC products that are available in many countries. The business strategy of Glenmark Pharmaceuticals is focused on growth and expansion. The company pursues an aggressive acquisition strategy and has made several acquisitions in recent years to expand its reach and capabilities. To further strengthen business development, Glenmark places great emphasis on innovation and research and development. The company invests a significant portion of its revenue in R&D activities to develop new groundbreaking therapies and medications. Glenmark's products are characterized by high quality, reliability, and effectiveness and are available in many countries around the world. The company has a carefully curated portfolio of products tailored to the needs of patients and the healthcare market. Through its investments in research and development and its acquisitions, Glenmark continuously strives for growth and expansion and is on track to take a leading role in the global pharmaceutical industry.
The revenue of Glenmark Pharmaceuticals is 167.11 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Glenmark Pharmaceuticals is 13.62 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Glenmark Pharmaceuticals is currently 55.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Glenmark Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Glenmark Pharmaceuticals is currently 4.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Glenmark Pharmaceuticals stock.
The Eulerpool Quality Score for Glenmark Pharmaceuticals is 6/10.
The ISIN of Glenmark Pharmaceuticals is INE935A01035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Glenmark Pharmaceuticals is GLENMARK.NS. The ticker symbol is used to trade Glenmark Pharmaceuticals shares on the stock exchange.
Glenmark Pharmaceuticals stock
Glenmark Pharmaceuticals Peer Group
Glenmark Pharmaceuticals Ticker
Glenmark Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Glenmark Pharmaceuticals
Our stock analysis for Glenmark Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Glenmark Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.